

HR 938

BLOCKING Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jan 31, 2019

Current Status: Placed on the Union Calendar, Calendar No. 24.

Latest Action: Placed on the Union Calendar, Calendar No. 24. (May 2, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/938>

Sponsor

Name: Rep. Schrader, Kurt [D-OR-5]

Party: Democratic • **State:** OR • **Chamber:** House

Cosponsors (16 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Carter, Earl L. "Buddy" [R-GA-1]	R · GA		Jan 31, 2019
Rep. Craig, Angie [D-MN-2]	D · MN		Mar 25, 2019
Rep. Dingell, Debbie [D-MI-12]	D · MI		Mar 26, 2019
Rep. Eshoo, Anna G. [D-CA-18]	D · CA		Mar 26, 2019
Rep. Pallone, Frank, Jr. [D-NJ-6]	D · NJ		Mar 26, 2019
Rep. Ruiz, Raul [D-CA-36]	D · CA		Mar 26, 2019
Rep. Kennedy, Joseph P., III [D-MA-4]	D · MA		Mar 27, 2019
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Mar 27, 2019
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Mar 27, 2019
Rep. Van Drew, Jefferson [D-NJ-2]	D · NJ		Mar 29, 2019
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		Apr 2, 2019
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Apr 8, 2019
Rep. Walden, Greg [R-OR-2]	R · OR		Apr 8, 2019
Rep. McAdams, Ben [D-UT-4]	D · UT		Apr 10, 2019
Rep. Mucarsel-Powell, Debbie [D-FL-26]	D · FL		Apr 29, 2019
Rep. Meadows, Mark [R-NC-11]	R · NC		May 1, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Reported by	Mar 27, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 19	Related bill	Dec 19, 2019: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
116 HR 2700	Related bill	Jun 26, 2019: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
116 HR 987	Related bill	May 20, 2019: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of May 2, 2019)

Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 or the BLOCKING Act of 2019

This bill modifies provisions related to market exclusivity for a generic drug.

Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug.

The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) a first applicant's application has been pending for at least 30 months, and (3) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant.

Actions Timeline

- **May 2, 2019:** Reported by the Committee on Energy and Commerce. H. Rept. 116-46.
- **May 2, 2019:** Placed on the Union Calendar, Calendar No. 24.
- **Apr 3, 2019:** Committee Consideration and Mark-up Session Held.
- **Apr 3, 2019:** Ordered to be Reported by Voice Vote.
- **Mar 27, 2019:** Subcommittee Consideration and Mark-up Session Held.
- **Mar 27, 2019:** Forwarded by Subcommittee to Full Committee by Voice Vote .
- **Feb 2, 2019:** Referred to the Subcommittee on Health.
- **Jan 31, 2019:** Introduced in House
- **Jan 31, 2019:** Referred to the House Committee on Energy and Commerce.